AlloVir

eye doctor opthalmology phoropter glasses eye disease vision
Biotech

AlloVir finds new identity via eye disease biotech merger

The all-stock transaction will create a combined company operating under the Kalaris brand and focused on Kalaris’ anti-VEGF drug.
James Waldron Nov 8, 2024 9:05am
spiral failure circle stuck lost missing lose

Reeling from triple phase 3 failure, AlloVir cuts 95% of staff

Jan 5, 2024 8:53am
Organ transplant

Triple phase 3 disaster sends AlloVir shares plunging 64%

Dec 22, 2023 9:00am
DNA strand gene editing

Moderna taps Life Edit to develop next-gen gene therapies

Feb 22, 2023 7:00am
A graphic displaying a cross-section of the kidneys

AlloVir's cell therapy tackles virus in kidney transplant trial

Feb 15, 2023 9:45am
Parachute

GSK cuts Slaoui ties over harassment claims—Chutes & Ladders

Mar 26, 2021 9:30am